CORAL SPRINGS, Fla., Oct. 28, 2011 /PRNewswire/ -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV/AIDS), Adrenomyeloneuropathy (AMN) and Pain, announced today that its Chief Executive Officer, Rik J. Deitsch, was interviewed by The Wall Street Reporter Senior Analyst Juan Costello. The interview provides an overview of the Company, its technology and an update on the Company's recent achievements. In addition, it provides a brief outlook of how Nutra Pharma views its business opportunities in the coming months.
"This interview has allowed us to provide some additional information on our two most recent press releases," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Recently, we announced the issuance of our newest patent that protects our drug technology for the treatment of Multiple Sclerosis. Additionally, we reported expanded international reach for our Nyloxin products through our new Distributor in Panama. The Company is now endeavoring to make it clear to the public that we have definitive short-term goals with the distribution of our drugs for the treatment of chronic pain; as well as long-term goals with our deep, drug discovery pipeline," he explained.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The interview on The Wall Street Reporter should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
|SOURCE Nutra Pharma Corporation|
Copyright©2010 PR Newswire.
All rights reserved